Vifor Pharma Licenses Marketing Rights to ChemoCentryx's CCX168 in Europe, Canada, Mexico, Central and S. America, S. Korea; ChemoCentryx to Receive Upfront Payment of $60M, Equity Investment of $25M @$7.50/Share
May 10, 2016 at 04:35 AM EDT
Vifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc. (Nasdaq: CCXI) announced today that Vifor Pharma has licensed ...
